Divergent immune landscapes of primary and syngeneic Kras-driven mouse tumor models

被引:0
作者
Wade R. Gutierrez
Amanda Scherer
Gavin R. McGivney
Qierra R. Brockman
Vickie Knepper-Adrian
Emily A. Laverty
Grace A. Roughton
Rebecca D. Dodd
机构
[1] University of Iowa,Cancer Biology Graduate Program, Carver College of Medicine
[2] University of Iowa,Medical Scientist Training Program
[3] University of Iowa,Holden Comprehensive Cancer Center
[4] University of Iowa,Molecular Medicine Graduate Program
[5] University of Iowa,Department of Internal Medicine
来源
Scientific Reports | / 11卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Immune cells play critical functions in cancer, and mice with intact immune systems are vital to understanding tumor immunology. Both genetically engineered mouse models (GEMMs) and syngeneic cell transplant approaches use immunocompetent mice to define immune-dependent events in tumor development and progression. Due to their rapid and reproducible nature, there is expanded interest in developing new syngeneic tools from established primary tumor models. However, few studies have examined the extent that syngeneic tumors reflect the immune profile of their originating primary models. Here, we describe comprehensive immunophenotyping of two well-established GEMMs and four new syngeneic models derived from these parental primary tumors. To our knowledge, this is the first systematic analysis comparing immune landscapes between primary and orthotopic syngeneic tumors. These models all use the same well-defined human-relevant driver mutations, arise at identical orthotopic locations, and are generated in mice of the same background strain. This allows for a direct and focused comparison of tumor immune landscapes in carefully controlled mouse models. We identify key differences between the immune infiltrate of GEMM models and their corresponding syngeneic tumors. Most notable is the divergence of T cell populations, with different proportions of CD8+ T cells and regulatory T cells across several models. We also observe immune variation across syngeneic tumors derived from the same primary model. These findings highlight the importance of immune variance across mouse modeling approaches, which has strong implications for the design of rigorous and reproducible translational studies.
引用
收藏
相关论文
共 77 条
  • [1] Day C-P(2015)Preclinical mouse cancer models: a maze of opportunities and challenges Cell 163 39-53
  • [2] Merlino G(2017)Genetically engineered mouse models in oncology research and cancer medicine EMBO Mol. Med. 9 137-153
  • [3] Van Dyke T(2016)Loss of PTEN promotes resistance to T cell-mediated immunotherapy Cancer Discov. 6 202-216
  • [4] Kersten K(2017)Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery Cancer Immunol. Res. 5 29-41
  • [5] de Visser KE(2018)Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments PLoS ONE 13 e0206223-489
  • [6] van Miltenburg MH(2013)Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy J. Immunother. 36 477-1391
  • [7] Jonkers J(2018)The antitumor activity of combinations of cytotoxic chemotherapy and immune checkpoint inhibitors is model-dependent Front. Immunol. 9 2100-54787
  • [8] Peng W(2018)Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains Cancer Immunol. Immunother. 67 1381-3360
  • [9] Mosely SIS(2017)Tumor location impacts immune response in mouse models of colon cancer Oncotarget 8 54775-175
  • [10] Yu JW(2019)The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy J. Clin. Invest. 129 3347-369